Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 22;12(10):1344.
doi: 10.3390/biom12101344.

From Small Peptides to Large Proteins against Alzheimer'sDisease

Pasquale Picone  1   2 , Tiziana Sanfilippo  3   4 , Sonya Vasto  2   5 , Sara Baldassano  2 , Rossella Guggino  3   4 , Domenico Nuzzo  1   2 , Donatella Bulone  6 , Pier Luigi San Biagio  6 , Emanuela Muscolino  7 , Roberto Monastero  8 , Clelia Dispenza  7 , Daniela Giacomazza  6
Affiliations
Review

From Small Peptides to Large Proteins against Alzheimer'sDisease

Pasquale Picone et al. Biomolecules. .

Abstract

Alzheimer's disease (AD) is the most common neurodegenerative disorder in the elderly. The two cardinal neuropathological hallmarks of AD are the senile plaques, which are extracellular deposits mainly constituted by beta-amyloids, and neurofibrillary tangles formed by abnormally phosphorylated Tau (p-Tau) located in the cytoplasm of neurons. Although the research has made relevant progress in the management of the disease, the treatment is still lacking. Only symptomatic medications exist for the disease, and, in the meantime, laboratories worldwide are investigating disease-modifying treatments for AD. In the present review, results centered on the use of peptides of different sizes involved in AD are presented.

Keywords: Alzheimer’s disease; Tau protein; amyloid-beta protein: amyloid fibrillation; neurofibrillary tangles.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Results of the different cleavage sites of APP by the secretase enzymes.
Figure 2
Figure 2
Scheme of the amyloid aggregation phases.
Figure 3
Figure 3
Results of the different human MAPT gene splicing in the expression of Tau isoforms.
Figure 4
Figure 4
Schematic view of the Abeta domains.
Figure 5
Figure 5
Scheme of the Abeta pathway in inducing impaired neuronal insulin signaling.
See this image and copyright information in PMC

References

    1. Picone P., Di Carlo M., Nuzzo D. Obesity and Alzheimer’s disease: Molecular bases. Eur. J. Neurosci. 2020;52:3944–3950. doi: 10.1111/ejn.14758. - DOI - PubMed
    1. Raudino F. Non-cognitive symptoms and related conditions in the Alzheimer’s Disease: A literature review. Neurol. Sci. 2013;34:1275–1282. doi: 10.1007/s10072-013-1424-7. - DOI - PubMed
    1. Jessen F., Amariglio R.E., van Boxtel M., Breteler M., Ceccaldi M., Chételat G., Dubois B., Dufouil C., Ellis K.A., van der Flier W.M., et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10:844–852. doi: 10.1016/j.jalz.2014.01.001. - DOI - PMC - PubMed
    1. Mariani E., Monastero R., Mecocci P. Mild cognitive impairment: A systematic review. J. Alzheimers Dis. 2007;12:23–35. doi: 10.3233/JAD-2007-12104. - DOI - PubMed
    1. Scheltens P., De Strooper B., Kivipelto M., Holstege H., Chételat G., Teunissen C.E., Cummings J., van der Flier W.M. Alzheimer’s disease. Lancet. 2021;397:1577–1590. doi: 10.1016/S0140-6736(20)32205-4. - DOI - PMC - PubMed

Publication types